NasdaqGS:AMGNBiotechs
A Look At Amgen (AMGN) Valuation After Strong Q4 Results And New UPLIZNA Approval
What Amgen’s latest quarter and new approval could mean for investors
Amgen (AMGN) is back on investors’ radar after reporting fourth quarter and full year 2025 results alongside fresh 2026 guidance, with European regulators also clearing a new use for its rare disease drug UPLIZNA.
Those updates arrive with the stock up around 12% over the past month and about 31% over the past year, raising the question of how much of this recent news is already reflected in the current US$369.19 share...